Peripheral Neuropathic Pain Market Size (7MM) was ~USD 12,000 Million in 2023, which is expected to increase by 2034, estimates DelveInsight

DelveInsight's "Peripheral Neuropathic Pain Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Peripheral Neuropathic Pain, historical and forecasted epidemiology as well as the Peripheral Neuropathic Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To know in detail about the Peripheral Neuropathic Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Peripheral Neuropathic Pain Market Forecast @ https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Peripheral Neuropathic Pain Market Report
• On December 10, 2025- Rigshospitalet, Denmark initiated a study is a randomized, double-blind, placebo-controlled trial, investigating the safety, efficacy, use of rescue medication, and impact on NPSI scores, health-related QoL, activities of daily living (ADLs) and levels of physical activity of perineural incobotulinumtoxin-A (iBonT-A) or placebo injections, in persons with DNP of the lower extremities.
• In November 2025, Vertex Pharmaceuticals Incorporated conducted a phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy.
• In November 2025, Eli Lilly and Company announced a study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee. Participation may last up to 30 weeks including screening.
• In 2023, the United States recorded the highest incidence of Peripheral Neuropathic Pain among the 7MM, with ~35,200,000 reported cases.
• The 7MM saw the highest number of severe cases in post-operative and post-traumatic Peripheral Neuropathic Pain, while moderate cases predominated in PHN in terms of severity.
• Estimates indicate that in 2023, the EU4 and the UK collectively reported approximately 19.3 million cases, with Germany representing the largest share at around 35% of the total cases.
• In 2023, diabetic peripheral neuropathy (DPN) accounted for the highest number of cases in the US, comprising approximately 50% of the total cases.
• The leading Peripheral Neuropathic Pain Companies such as Grünenthal and Averitas Pharma, Scilex Pharmaceuticals, Apurano Pharmaceuticals, Lexicon Pharmaceuticals, Wex Pharmaceuticals, Helixmith, Lexicon Pharmaceuticals Inc., Bayer, AlzeCure Pharma, Grünenthal, Mallinckrodt Pharmaceuticals., Pfizer, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., and others
• Promising Peripheral Neuropathic Pain Therapies such as QUTENZA (capsaicin), ZTLIDO (lidocaine), SEMDEXA (SP-102), Adezunap (AP707), LX9211, Halneuron (Tetrodotoxin or TTX), ENGENSIS/VM202 (donaperminogene seltoplasmid), Halneuron, LX9211, BAY2395840, ACD440 gel, and others.

Get a Free sample for the Peripheral Neuropathic Pain Market Report @ https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral Neuropathic Pain Epidemiology Segmentation in the 7MM
• Total Cases of Peripheral Neuropathic Pain in the 7MM
• Type-specific Cases of Peripheral Neuropathic Pain in the 7MM
• Treated Cases of Peripheral Neuropathic Pain in the 7MM

Download the report to understand which factors are driving Peripheral Neuropathic Pain epidemiology trends @ Peripheral Neuropathic Pain Prevalence- https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marketed Peripheral neuropathic pain Drugs
• QUTENZA (capsaicin): Grünenthal and Averitas Pharma
QUTENZA (capsaicin) 8% topical system, a non-systemic, non-opioid pain relief delivered in the form of a patch, indicated for treating neuropathic pain associated with postherpetic neuralgia or associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Capsaicin is an agonist for the transient receptor potential vanilloid 1 receptor (TRPV1), an ion channel-receptor complex expressed on nociceptive nerve fibers in the skin. QUTENZA is marketed and distributed by Averitas. Currently, it is being evaluated under a Phase III trial in post-surgical neuropathic pain. The trial is expected to be completed by October 2024, with an estimated enrollment of 408 participants.

• ZTLIDO (lidocaine): Scilex Pharmaceuticals
ZTLIDO is a topical lidocaine system (1.8%) approved for relieving pain associated with postherpetic neuralgia. ZTLIDO is designed as a lighter, thinner product with improved adhesion relative to LIDODERM (lidocaine patch 5%) while providing a bioequivalent delivery of lidocaine in an efficient drug delivery system. Lidocaine is a local amide anesthetic; it blocks sodium ion channels required for initiating and conducting neuronal impulses. Patients are advised to apply ZTLIDO to intact skin to cover the most painful area and to apply the prescribed number of topical systems (maximum of three) only once for up to 12 h within 24 h (12 h on and 12 h off). Smaller areas of treatment are recommended in patients who are debilitated or have impaired elimination. Achieve this by cutting ZTLIDO with scissors into a smaller size before removing the release liner.

Emerging Peripheral neuropathic pain Drugs
• SEMDEXA (SP-102): Scilex Holding Company
SP-102 is a preservative-free, surfactant-free, and particulate-free, novel epidural steroid injection (ESI) formulation of 10 mg dexamethasone sodium phosphate in a viscous gel solution for subacute lumbosacral radicular pain (Sciatica). Its extended local effect provides durable pain relief and significant improvement in functioning from a single injection with rapid onset. Recently, the company has completed a pivotal Phase III (NCT03372161) Corticosteroid Lumbar Epidural Analgesia ("CLEAR") trial, which was designed to evaluate the safety and efficacy of SP-102 in Lumbosacral Radiculopathy ( or Sciatica).

• Adezunap (AP707): Apurano Pharmaceuticals
Apurano Pharmaceuticals' investigational drug AP707, featuring the focused active ingredient adezunap, has received EMA approval for DISCOVER approval studies. Utilizing the patented PuranoTec manufacturing process, cannabis flower undergoes processing to create an aqueous nanodispersion of cannabinoids, primarily. Administered as a sublingual mouth spray, this dispersion allows for rapid and efficient absorption through the oral mucosa, facilitated by a water-soluble shell termed the smart coating. These SmartLipids, encapsulating lipophilic cannabinoids, remain stable in aqueous environments and can directly enter the bloodstream due to their small particle size (

About Us

DelveInsight is a leading healtcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healtcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.